Skip to main content
. 2022 Sep 5;13:968206. doi: 10.3389/fimmu.2022.968206

Table 1.

Myasthenia Gravis patient categories according to how the patient Ig mediates AChR loss, MAC deposition and effect of C7 inhibition.

MG Patient AChR Loss AChR Loss blocked by anti-C7 Ab? MAC Deposition IgG Cell Binding Anti-AChR Titre (nmol/L) Category
2 ++ Yes + ++ 5.43 1
3 ++ Yes ++ +++ 143.49 1
14 ++ Yes + ++ 13.65 1
15 ++ Yes + ++ 12.09 1
16 ++ Yes + ++ 23.60 1
17 ++ Yes ++ +++ 67.52 1
MSDN04 ++ Yes (Partially) +++ +++ 130.32 1
MSDN09 ++ Yes +++ +++ 1.78 1
MSDN19 ++ Yes (Partially) +++ +++ 53.84 1
4 + Yes - ++ 4.80 2
12 + Yes - ++ 10.13 2
13 + Yes - + 3.80 2
1 - N/A - ++ 18.40 3
5 - N/A - + 16.28 4
8 - N/A - + 2.18 4
9 - N/A - + 3.21 4
11 - N/A - + 4.37 4
18 - N/A - - 41.89 4
MSDN12 - N/A + - <Detection Range 4
Pooled Ctrl Plasma - N/A - - <Detection Range N/A
Max Scale ++ +++ +++

N/A, not applicable.